Prime Medicine, Inc. PRME 深 滬
等待開盤 06-30 09:30:00 美东时间
3.72
+0.290
+8.45%
華盛通- 最 高3.94
- 今 開3.73
- 成交量 529.44万股
- 最 低 3.58
- 昨 收 3.43
- 總市值 6.72亿
- 52周最高 6.94
- 市盈率 靜 --
- 換手率 2.93%
- 52周最低 2.67
- 委 比 72.11%
- 總股本 1.81亿
- 歷史最高 21.73
- 量 比 1.27
- 振 幅 10.50%
- 歷史最低 1.11
- 每 手 1
- 風險率 0.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
今天 10:14
Iridium Communications, FuelCell Energy, Rocket Lab And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 350 points on Monday. Shares of Iridium Communications Inc (NASDAQ:IRDM) rose sharply after the company announced it will be acquired by Rocket Lab. Rocket Lab and Iridium Communications announced Monday that they have entered into a d...
06-29 21:58
This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Arthur He upgraded Prime Medicine, Inc (NASDAQ:PRME) from Neutral to ...
06-29 20:42
HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target
HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $8 price target.
06-29 18:13
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.
05-27 22:51
Prime Medicine shares are trading lower after the company reported worse-than-expected Q1 sales results.
Prime Medicine shares are trading lower after the company reported worse-than-e...
05-08 00:58
Prime Medicine Q1 EPS $(0.28) Misses $(0.25) Estimate, Sales $856.000K Miss $1.065M Estimate
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.25) by 12 percent. This is a 30 percent increase over losses of $(0.40) per share from the
05-07 20:17
Advanced Cell-based Therapy Booming the Success for Healthcare Sector
Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 24, 2026 /PRNewswire/ -- USANewsGroup.com — The FDA has approved more than 40 cell and gene therapy products. The regenerative medicin...
03-24 22:00
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11
Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $11.
03-13 01:13
